At a time that is now defined by significant technological change and persistent regulatory pressures, pharmaceutical manufacturing executives continue to face a new set of operational challenges.
Traditional models, once the bedrock of drug production success, are no longer sufficient to navigate the need for sterile environments, a scarcity of highly skilled technicians, supply chain volatility and the relentless demand for patient-specific therapies and greater efficiency.
For many, especially the small and medium-sized biotechs and contract development and manufacturing organisations (CDMOs) that form the backbone of the American industrial landscape, these hurdles can seem insurmountable.
Yet, a new paradigm is emerging: Industry 5.0 offers a powerful solution — not by replacing the human workforce but by augmenting it with a revolution in machine-based collaboration.
Dijam Panigrahi, COO and cofounder of GridRaster Inc., reports.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.